Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Study acronym: Detect-AD
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 10 → 13 locations
  2. Trial sites expanded: 4 → 10 locations
    • Start date changed from estimate of May 29, 2026 to Jun 4, 2026
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 5 entries
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Trial Details
NCT Number NCT07645820
Lead Sponsor Castle Biosciences Incorporated
Collaborators: SciBase AB
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic, Eczema
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov